C. McCoach

发表

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Lawrence H. Schwartz, Donald A. Berry, Janis M. Taube, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation

C. Blakely, D. Jablons, T. Bivona, 2019, Clinical lung cancer.

Adherence to Guideline‐Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease

H. Bang, E. Amsterdam, J. Laird, 2014, Journal of the American Heart Association.

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer

E. Collisson, F. Kaye, I. Yeh, 2018 .

Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

C. McCoach, F. Sun, 2021, Current Treatment Options in Oncology.

A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy.

C. McCoach, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Engineering Multidimensional Evolutionary Forces to Combat Cancer.

T. Bivona, C. McCoach, 2019, Cancer discovery.

Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase 1/2 LIBRETTO-001Trial.

L. Wirth, V. Subbiah, V. Boni, 2021, The oncologist.

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

Kenneth L. Jones, P. Bunn, M. Varella‐Garcia, 2018, Clinical Cancer Research.

Fungating Mass as First Presentation of Advanced Breast Cancer

P. Aronowitz, C. McCoach, 2014, Journal of General Internal Medicine.

E. Amsterdam, J. Laird, K. Yeo, 2013, Vascular medicine.

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

A. Drilon, M. Burkard, Melissa L. Johnson, 2019, Journal of Thoracic Oncology.

Registrational results of LOXO-292 in patients with RET-altered thyroid cancers

A. Drilon, T. Owonikoko, B. Solomon, 2019, Annals of Oncology.

NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types

A. Drilon, J. Subramanian, A. Bardia, 2021, British Journal of Cancer.

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial.

L. Wirth, V. Subbiah, V. Boni, 2021, The oncologist.

The role of APOBEC3B in lung tumour evolution and targeted therapy resistance

E. V. Van Allen, R. Harris, W. Brown, 2022, bioRxiv.

Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

A. Drilon, L. Bazhenova, B. Konda, 2021, Clinical Trials.

Brain Metastases in EGFR- and ALK- Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation

N. Myall, H. Wakelee, D. Camidge, 2022 .

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing

Erin L. Schenk, Sourav Bandyopadhyay, N. Neff, 2020, Cell.

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

Sourav Bandyopadhyay, J. Roth, J. Riess, 2021, bioRxiv.

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

A. Drilon, Keunchil Park, Y. Ohe, 2020, The New England journal of medicine.

Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.

J. Neal, Jianchang Lin, L. Horn, 2020 .

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy

R. Doebele, P. Keegan, R. Pazdur, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Heterogeneity and targeted therapy-induced adaptations in lung cancer revealed by longitudinal single-cell RNA sequencing

Erin L. Schenk, N. Neff, J. Weissman, 2019, bioRxiv.

Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer

C. McCoach, A. Velazquez, 2020, Journal of thoracic disease.

Systematic Identification of Balanced Transposition Polymorphisms in Saccharomyces cerevisiae

Todd J. Vision, Joseph K. Pickrell, J. Lieb, 2009, PLoS genetics.

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

L. Beckett, J. Riess, K. Kelly, 2021, JCO precision oncology.

Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations.

D. Gandara, F. Meric-Bernstam, J. Crawford, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

E. Collisson, F. Kaye, I. Yeh, 2019, Clinical Cancer Research.

Co-occurring genetic alterations in the RAS pathway promote resistance to MET inhibitor treatment in non-small cell lung cancer with a MET exon 14 skipping mutation

E. Collisson, F. Kaye, I. Yeh, 2018, bioRxiv.

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

G. Kiss, M. Goldsmith, Mallika Singh, 2018, Nature Cell Biology.

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

Maximilian Diehn, Charles Swanton, Wei Wu, 2017, Nature Genetics.

Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.

R. Doebele, C. Blakely, T. Bivona, 2016, Clinical lung cancer.

The Minority Report: Targeting the Rare Oncogenes in NSCLC

R. Doebele, C. McCoach, 2014, Current Treatment Options in Oncology.

Treatment paradigms in advanced non-small-cell lung cancer.

K. Kelly, C. McCoach, 2013, Clinical advances in hematology & oncology : H&O.

Phase I study of INC280 plus erlotinib in patients with MET expressing adenocarcinoma of the lung.

L. Beckett, J. Riess, K. Kelly, 2015 .

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

R. Doebele, Jihye Kim, A. Tan, 2021, npj Precision Oncology.

Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose‐ and sequence‐dependent manner

M. Varella‐Garcia, D. Raben, T. Flaig, 2009, BJU international.

NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types

A. Drilon, J. Subramanian, A. Bardia, 2021, British Journal of Cancer.

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.

J. Riess, R. Doebele, R. Nichols, 2018, Cancer research.

Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancers

V. Wang, C. Swanton, J. Chabon, 2017, bioRxiv.

Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance

E. V. Van Allen, W. Brown, A. Rowan, 2020, bioRxiv.

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

A. Drilon, Keunchil Park, B. Cho, 2021, Clinical Cancer Research.

Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.

Summer S. Han, J. Neal, H. Wakelee, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

S. Digumarthy, J. Neal, H. Wakelee, 2023, JTO clinical and research reports.

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

A. Shaw, R. Doebele, K. Davies, 2018, Clinical Cancer Research.

First‐line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non–Small‐cell Lung Cancer With Different Prognostic Significance

K. Kelly, R. Camidge, R. Doebele, 2018, Clinical lung cancer.

A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial

P. Jänne, J. Riess, S. Ou, 2020 .

Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer.

M. Mino‐Kenudson, L. Sequist, S. Ou, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Acral Lentiginous Melanoma Harboring a ROS1 Gene Fusion With Clinical Response to Entrectinib.

R. Doebele, K. Lewis, J. Christiansen, 2017, JCO precision oncology.

Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.

N. Myall, H. Wakelee, D. Camidge, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer.

D. Dwyre, C. McCoach, B. Jonas, 2015, Cancer treatment communications.

The evolving understanding of immunoediting and the clinical impact of immune escape.

T. Bivona, C. McCoach, 2018, Journal of thoracic disease.

Current Trial Report Neoadjuvant Oncogene-Targeted Therapy in Early Stage NoneSmall-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance

R. Doebele, C. Blakely, T. Bivona, 2016 .

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.

R. Doebele, P. Keegan, R. Pazdur, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells

K. Wood, C. Blakely, T. Bivona, 2022, Science Translational Medicine.

1922P Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO-292)

D. Tan, L. Wirth, V. Subbiah, 2020 .

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

A. Drilon, Keunchil Park, M. Lacouture, 2022 .

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.

R. Doebele, P. Keegan, R. Pazdur, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

A. Drilon, Keunchil Park, M. Lacouture, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions

Erin L. Schenk, T. Burns, D. Camidge, 2020 .

In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"

N. Myall, H. Wakelee, D. Camidge, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.

J. Neal, H. Wakelee, J. Riess, 2020, Journal of Clinical Oncology.

Exploratory responder analyses of greatest depth of response (DepOR) and survival in patients with metastatic non-small cell lung cancer (mNSCLC) treated with a targeted therapy or immunotherapy.

R. Doebele, P. Keegan, R. Pazdur, 2016 .

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry

R. Camidge, A. Baron, E. Berge, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

J. Riess, S. Ou, J. Bendell, 2020, European Journal of Cancer.

Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.

A. Jimeno, C. McCoach, 2016, Drugs of today.

FP14.06 Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study

J. Nieva, R. Camidge, R. Doebele, 2021, Journal of Thoracic Oncology.

Evolution and clinical impact of genomic alterations detectable in circulating tumor DNA of 1150 advanced EGFR-mutant (mt) lung cancer patients.

V. Wang, J. Riess, R. Doebele, 2017 .

Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC)

A. Drilon, J. Wolf, B. Besse, 2020, Pneumologie.

Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies

C. Blakely, C. McCoach, 2020, Clinical Cancer Research.

Abstract LB001: Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers

P. Jänne, J. Riess, H. Burris, 2021, Experimental and Molecular Therapeutics.

The importance of the initial response to cancer treatment in predicting longer overall survival

R. Doebele, C. McCoach, 2018, Expert review of clinical pharmacology.

1291P Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI)

K. Goto, D. Tan, C. Rolfo, 2020 .

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

G. Kiss, M. Goldsmith, Mallika Singh, 2018, Nature Cell Biology.

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry

R. Camidge, A. Baron, C. McCoach, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.